Patents Assigned to Biohaven Therapeutics Ltd.
  • Prodrugs of riluzole and their method of use
    Patent number: 11911369
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: February 27, 2024
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian
  • Benzoimidazol-1,2-yl amides as Kv7 channel activators
    Patent number: 11834418
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: December 5, 2023
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Lynn Resnick, George T. Topalov, Justin K. Belardi, James S. Hale, Scott S. Harried, Charles A. Flentge, David A. Mareska
  • Kv7 channel activators compositions and methods of use
    Patent number: 11724990
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Grant
    Filed: January 7, 2022
    Date of Patent: August 15, 2023
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Michael E. Bozik, Scott S. Harried, Lynn Resnick, George T. Topalov, Justin K. Belardi, Charles A. Flentge, David A. Mareska, James S. Hale
  • Sublingual formulation of riluzole
    Patent number: 11660267
    Abstract: Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: May 30, 2023
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Vladimir Coric, Robert Berman, Ronald S. Vladyka, Amgad Saleh, Danny Yu
  • CD16A binding agents and uses thereof
    Patent number: 11572370
    Abstract: Among other things, the present disclosure provides compounds, compositions thereof, and methods of using the same. In some embodiments, compounds of the present disclosure bind to Fc receptors, e.g., CD16a. In some embodiments, compounds of the present disclosure are useful for treating various conditions, disorders or diseases including cancer.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: February 7, 2023
    Assignee: BIOHAVEN THERAPEUTICS LTD.
    Inventors: Anna Bunin, Lawrence G. Iben, Douglas Manion, David Adam Spiegel, Matthew Ernest Welsch
  • PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE
    Publication number: 20220396555
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Application
    Filed: May 4, 2020
    Publication date: December 15, 2022
    Applicant: Biohaven Therapeutics Ltd.
    Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian
  • Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers
    Patent number: 11400155
    Abstract: Disclosed are methods of treating cancer using a combination of an immunotherapeutic agent, such as, for example, a PD-1, PD-L1 or CTLA-4 checkpoint inhibitor, and a glutamate modulating agent such as riluzole or trigriluzole. Pharmaceutical compositions including the immunotherapeutic agents and glutamate modulating agents are also disclosed.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: August 2, 2022
    Assignee: Biohaven Therapeutics Ltd.
    Inventor: Vladimir Coric
  • Amine prodrugs of pharmaceutical compounds
    Patent number: 11083711
    Abstract: Disclose are amine prodrugs and methods of synthesis thereof. In particular, the amine prodrug comprises a drug molecule and at least one or more prodrug appendage moieties and the method for synthesis the amine prodrug comprises a step of coupling the drug molecule and at least one or more prodrug appendage moieties. Also disclosed are exemplary riluzole prodrugs and methods of synthesis thereof.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: August 10, 2021
    Assignee: Biohaven Therapeutics Ltd.
    Inventor: Anthony Marfat
  • Riluzole prodrugs and their use
    Patent number: 11052070
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: July 6, 2021
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian
  • Riluzole prodrugs and their use
    Patent number: 10905681
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: February 2, 2021
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Jay Edward Wrobel, Allen B. Reitz, Jefferey Claude Pelletier, Garry Robert Smith, Haiyan Bian
  • Prodrugs of riluzole and their method of use
    Patent number: 10639298
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: May 5, 2020
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian
  • RILUZOLE PRODRUGS AND THEIR USE
    Publication number: 20200085794
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Application
    Filed: November 20, 2019
    Publication date: March 19, 2020
    Applicant: Biohaven Therapeutics Ltd.
    Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian
  • Riluzole prodrugs and their use
    Patent number: 10485791
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: November 26, 2019
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian